{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:36:22Z","timestamp":1769603782327,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Therapeutic approaches for cancer rely on careful consideration of finding the optimal way of delivering the pro-drug for cellular-based cancer treatment. Cell lines and cell cultures have been used in these studies to compare the in vitro and in vivo efficacy of autologous vs. allogeneic tumour cellular gene therapy. Here we have investigated and are reporting for the first time the effect of prodrug ganciclovir (GCV)-preloading (pre-treatment) in suicide gene therapy of cancer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This study examines the effect of GCV-preloading (pre-treatment) on a range of tumour cell lines in conjunction with suicide gene therapy of cancer. To determine the efficacy of this modality, a series of in vitro and in vivo experiments were conducted using genetically modified and unmodified tumour cell lines.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Following co-culture of herpes simplex virus thymidine kinase (HSV-TK) modified tumour cells and unmodified tumour cells both in vitro and in vivo, GCV-preloading (pre-treatment) of TK-modified human and mouse mesothelioma cells and ovarian tumour cells allowed them to mediate efficiently bystander killing of neighbouring unmodified tumour cells in vitro. In contrast, GCV-preloading of TK-modified human and mouse mesothelioma cells and ovarian tumour cells abolished their in vivo ability to induce bystander killing of unmodified tumour cells, although there was some tumour regression compared to control groups but this was not statistically significant. These results suggest that preloading TK modified tumour cells with GCV needs further study to define the most effective strategy for an in vivo application to retain their bystander killing potential after exposure to lethal doses of GCV in vitro.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study highlights the promising possibility of improving the efficacy of pro-drug system to prevent any damage to the immune system and enhancing this type of suicide gene therapy of cancer, as well as the need for further studies to explore the discrepancies between in vitro and in vivo results.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12935-020-1115-4","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T11:02:56Z","timestamp":1580209376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Demonstration of anti-tumour bystander killing with prodrug-preloaded suicide gene-engineered tumour cells: a potential improvement for cancer therapeutics"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-0972","authenticated-orcid":false,"given":"Jehad","family":"Zweiri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8925-3204","authenticated-orcid":false,"given":"Stephen E.","family":"Christmas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,28]]},"reference":[{"key":"1115_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/cgt.2010.40","volume":"17","author":"B Sangro","year":"2010","unstructured":"Sangro B, Mazzolini G, Ruiz M, Ruiz J, Quiroga J, Herrero I, et al. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther. 2010;17:837\u201343. https:\/\/doi.org\/10.1038\/cgt.2010.40.","journal-title":"Cancer Gene Ther"},{"key":"1115_CR2","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1089\/hum.1998.9.17-2595","volume":"9","author":"D Klatzmann","year":"1998","unstructured":"Klatzmann D, Val\u00e9ry CA, Bensimon G, Marro B, Boyer O, Mokhtari K, et al. A phase I\/II study of herpes simplex virus type 1 thymidine kinase \u2018suicide\u2019 gene therapy for recurrent glioblastoma. Hum Gene Ther. 1998;9:2595\u2013604. https:\/\/doi.org\/10.1089\/hum.1998.9.17-2595.","journal-title":"Hum Gene Ther"},{"key":"1115_CR3","first-page":"5276","volume":"46","author":"FL Moolten","year":"1996","unstructured":"Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1996;46:5276\u201380.","journal-title":"Cancer Res"},{"key":"1115_CR4","first-page":"279","volume":"1","author":"FL Moolten","year":"1994","unstructured":"Moolten FL. Drug sensitivity (\u201csuicide\u201d) genes for selective cancer chemotherapy. Cancer Gene Ther. 1994;1:279\u201382.","journal-title":"Cancer Gene Ther"},{"key":"1115_CR5","doi-asserted-by":"publisher","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","volume":"74","author":"GB Elion","year":"1977","unstructured":"Elion GB, Furman PA. Selectivity of action of an antiherpetic agent. Proc Nat Acad Sci USA. 1977;74:5716\u201360.","journal-title":"Proc Nat Acad Sci USA"},{"key":"1115_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/1357-4310(96)88774-0","volume":"2","author":"M Caruso","year":"1996","unstructured":"Caruso M. Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Mol Med Today. 1996;2:212\u20137.","journal-title":"Mol Med Today."},{"key":"1115_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/BF00046344","volume":"15","author":"LA Martin","year":"1996","unstructured":"Martin LA, Lemoine NR. Direct cell killing by suicide genes. Cancer Metastases Rev. 1996;15:301\u20135.","journal-title":"Cancer Metastases Rev."},{"key":"1115_CR8","first-page":"5274","volume":"53","author":"SM Freeman","year":"1993","unstructured":"Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN. The bystander effect-tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274\u201383.","journal-title":"Cancer Res"},{"key":"1115_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/hum.1996.7.2-141","volume":"7","author":"AA Elshami","year":"1996","unstructured":"Elshami AA, Kucharczuk JC, Zhang HB, Smythe WR, Hwang HC, Litzky LA, Kaiser LR, Albelda SM. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther. 1996;7:141\u20138. https:\/\/doi.org\/10.1089\/hum.1996.7.2-141.","journal-title":"Hum Gene Ther"},{"key":"1115_CR10","first-page":"85","volume":"3","author":"AA Elshami","year":"1996","unstructured":"Elshami AA, Saavedra A, Zhang H, Kucharzuk JC, Spray DC, Fishman GI, et al. Gap junctions play a role in the \u201cbystander effect\u201d of the herpes simplex virus thymidine kinase\/ganciclovir system in vitro. Gene Ther. 1996;3:85\u201392.","journal-title":"Gene Ther"},{"key":"1115_CR11","first-page":"326","volume":"1","author":"SM Freeman","year":"1994","unstructured":"Freeman SM, Ramesh R, Marrogi AJ, Jensen A, Abboud CN. In vivo studies on the mechanisms of bystander effect. Cancer Gene Ther. 1994;1:326\u201332.","journal-title":"Cancer Gene Ther"},{"key":"1115_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0140-6736(97)22001-5","volume":"349","author":"SM Freeman","year":"1997","unstructured":"Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet. 1997;349:2\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(97)22001-5.","journal-title":"Lancet"},{"key":"1115_CR13","first-page":"240","volume":"2","author":"SM Freeman","year":"1995","unstructured":"Freeman SM. Enhanced tumour recognition and killing using the HSV-TK suicide gene. Cancer Gene Ther. 1995;2:240\u20131.","journal-title":"Cancer Gene Ther"},{"key":"1115_CR14","unstructured":"Goodman and Gilman\u2019s. The pharmacological basis of therapeutics. Ninth edition, 1200\u20131202, 1996."},{"key":"1115_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0140-6736(96)02266-0","volume":"349","author":"SM Freeman","year":"1997","unstructured":"Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet. 1997;349:20\u201330.","journal-title":"Lancet"},{"key":"1115_CR16","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1089\/hum.1995.6.7-927","volume":"6","author":"SM Freeman","year":"1995","unstructured":"Freeman SM, McCune C, Robinson W, Abboud CN, Abraham GN, Angel C, et al. The treatment of ovarian cancer with a gene modified cancer vaccine: a phase I study. Hum Gene Ther. 1995;6:927\u201339. https:\/\/doi.org\/10.1089\/hum.1995.6.7-927.","journal-title":"Hum Gene Ther"},{"key":"1115_CR17","first-page":"17","volume":"5","author":"N Shivapurkar","year":"1999","unstructured":"Shivapurkar N, Virmani AK, Wistuba II, Milchgrub S, Mackay B, Minna JD, et al. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res. 1999;5:17\u201323.","journal-title":"Clin Cancer Res."},{"key":"1115_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1385\/0-89603-484-4:59","volume-title":"Methods in molecular medicine, gene therapy protocols","author":"I Riviere","year":"1997","unstructured":"Riviere I, Sadelain M. Methods for the construction of retroviral vectors and the generation of high-titer producers. In: Robbins P, editor. Methods in molecular medicine, gene therapy protocols. New Jersey: Humana Press; 1997. p. 59\u201378. https:\/\/doi.org\/10.1385\/0-89603-484-4:59."},{"key":"1115_CR19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0042-6822(88)90101-8","volume":"167","author":"D Markowitz","year":"1988","unstructured":"Markowitz D, Goff A, Bank A. Construction of a safe and efficient amphotropic packaging cell line. Virology. 1988;167:400\u20136.","journal-title":"Virology"},{"key":"1115_CR20","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1128\/JVI.65.5.2220-2224.1991","volume":"65","author":"A Miller","year":"1991","unstructured":"Miller A. Construction and properties of retrovirus packaging cells based on gibbon ape leukaemia virus. J Virol. 1991;65:2890\u20137.","journal-title":"J Virol"},{"key":"1115_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"TM Mosmann","year":"1983","unstructured":"Mosmann TM. Rapid colorimetric assay for cellular growth and survival. J Immunol Methods. 1983;65:55\u201363.","journal-title":"J Immunol Methods"},{"key":"1115_CR22","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/sj.gt.3300784","volume":"5","author":"RL Touraine","year":"1998","unstructured":"Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVTK\/GCV system and its relationship to a gap junctional communication. Gene Therapy. 1998;5:1705\u201311. https:\/\/doi.org\/10.1038\/sj.gt.3300784.","journal-title":"Gene Therapy."},{"key":"1115_CR23","first-page":"31","volume":"23","author":"SM Freeman","year":"1996","unstructured":"Freeman SM. In situ use of suicide genes for cancer therapy. Semin Oncol. 1996;23:31\u201345.","journal-title":"Semin Oncol"},{"key":"1115_CR24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1089\/hum.1993.4.6-725","volume":"4","author":"B Wanli","year":"1993","unstructured":"Wanli B. In vitro evidence that metabolic co-operation is responsible for the bystander effect observed with HSV-TK retroviral gene therapy. Hum Gene Ther. 1993;4:725\u201331.","journal-title":"Hum Gene Ther"},{"key":"1115_CR25","first-page":"2697","volume":"56","author":"W Hamel","year":"1996","unstructured":"Hamel W, Magnelli L, Chiarugi VP, Israel MA. Herpes simplex virus thymidine kinase\/gancyclovir-mediated apoptotic death of bystander cells. Cancer Res. 1996;56:2697\u201327021.","journal-title":"Cancer Res"},{"key":"1115_CR26","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1089\/10430349950017879","volume":"10","author":"C Englmann","year":"1999","unstructured":"Englmann C, Panis Y, Bolard J, Dertrand D, Klatzman D. Liposomal encapsulation of GCV enhances the efficacy of HSVTK type 1 suicide gene therapy against hepatic tumour in rat. Hum Gene Ther. 1999;10:1545\u201351.","journal-title":"Hum Gene Ther"},{"key":"1115_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/sj.gt.3300379","volume":"4","author":"H Ishii-Morita","year":"1997","unstructured":"Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin DA, Ram Z, et al. Mechanism of \u201cbystander effect\u201d killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 1997;4:244\u201351. https:\/\/doi.org\/10.1038\/sj.gt.3300379.","journal-title":"Gene Ther"},{"key":"1115_CR28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1089\/hum.1998.9.6-801","volume":"9","author":"PD Boucher","year":"1998","unstructured":"Boucher PD, Ruch RJ, Shewach DS. Diferential gancyclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Hum Gene Ther. 1998;9:801\u20134.","journal-title":"Hum Gene Ther"},{"key":"1115_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<267::AID-IJC23>3.0.CO;2-D","volume":"71","author":"RG Vile","year":"1997","unstructured":"Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSV-TK killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer. 1997;71:267\u201374.","journal-title":"Int J Cancer"},{"key":"1115_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1566523033347426","volume":"3","author":"C Fillat","year":"2003","unstructured":"Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene\/ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13\u201326.","journal-title":"Curr Gene Ther"},{"key":"1115_CR31","doi-asserted-by":"publisher","first-page":"16849","DOI":"10.4172\/2157-7412.1000139","volume":"4","author":"P Zarogoulidis","year":"2013","unstructured":"Zarogoulidis P, Darwiche K, Sakkas A, Yarmus L, Huang H, Li Q, et al. Suicide gene therapy for cancer\u2014current strategies. J Genet Syndr Gene Ther. 2013;4:16849. https:\/\/doi.org\/10.4172\/2157-7412.1000139.","journal-title":"J Genet Syndr Gene Ther"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-1115-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12935-020-1115-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-020-1115-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T00:15:56Z","timestamp":1611706556000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-020-1115-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,28]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1115"],"URL":"https:\/\/doi.org\/10.1186\/s12935-020-1115-4","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,28]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research received the support and was also approved by the Ethics Committee of the Rayne Institute, King\u2019s College London, UK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication are not required, no parts of this manuscript are being considered for publication elsewhere.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}